Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.

Abstract

BACKGROUND: To define surgical outcomes of patients with high-grade gastro-entero-pancreatic neuroendocrine neoplasm grade G3 (GEP-NEN G3).METHODS: Patients who underwent surgical resection between 2000 and 2016 were identified. The overallsurvival(OS) and recurrence-free survival (RFS) of patients withgastro-entero-pancreatic neuroendocrine tumors grade G3(GEP-NET G3)versus neuroendocrine carcinoma (NEC) were evaluated.RESULTS: Fifty-one out of 2182 (2.3%) patients who underwent surgical resection were diagnosed as GEP-NEN G3. The pancreas was the most common primary site (n=3772.5%). A majority of patients had lymph node metastasis (n=3262.7%); one in three (n=1631.4%) had distant metastasis. The median OS and RFS of the entire cohort were 56.4and 34.5 months, respectively. Perineural invasionwas a strong prognostic factor associate with OS after surgical resection. Patients with NEC had a worse survival outcome versus patients with NET G3 (median OS: 33.1 months vs. not attained, p=0.088). In contrast, among patients who underwent curative-intent resection, patients with NEC had comparable RFS versus patients with NET G3 (median RFS: 35.6 vs. 33.9 months, p=0.774).CONCLUSIONS: Surgical resection provided acceptable short- and long-outcomes for well-selected patients with resectable GEP-NEN G3. NEC was associated with a worse OS versus NET G3.

View details for DOI 10.1002/jso.26928

View details for PubMedID 35616186